Bristol-Myers Squibb's (BMY) and AbbVie's (ABBV) Elotuzumab helped patients with...

|About: AbbVie Inc. (ABBV)|By:, SA News Editor

Bristol-Myers Squibb's (BMY) and AbbVie's (ABBV) Elotuzumab helped patients with previously-treated multiple myeloma live for a median 33 months without the blood cancer getting worse in a Phase II trial. The drug was given with Celgene's (CELG) Revlimid and the steroid dexamethasone. Elotuzumab is also being tested in two Phase III trials for multiple myeloma. (PR)

Subscribe for full text news in your inbox